Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Innovimmune Biotherapeutics, Inc. is a privately held, preclinical-stage biopharmaceutical company dedicated to the discovery and development of novel, first-in-class small molecule immunotherapies. The company's primary focus is on creating treatments for cancer, autoimmune diseases, and inflammatory diseases by modulating the innate immune system. Their innovative pipeline aims to address significant unmet medical needs by offering new therapeutic options to patients.
Core research and development activities, particularly preclinical studies for its immunotherapy pipeline, along with corporate management and strategic planning.
Situated in the Alexandria Center for Life Science, providing access to advanced laboratory facilities, shared amenities, and a vibrant ecosystem of peer biotech companies and research institutions.
A dynamic, scientifically-driven environment characterized by intensive research, innovation, and collaboration, typical of early-stage biopharmaceutical ventures focused on breakthrough therapies.
The New York City location, specifically within a major life science cluster like the Alexandria Center, offers strategic advantages in talent acquisition, scientific collaboration, and proximity to financial markets and potential partners.
As a preclinical-stage biopharmaceutical company based in the United States, Innovimmune Biotherapeutics, Inc. primarily focuses its operations, including research and development, within the US. Its global presence at this stage is likely centered on scientific collaborations, participation in international conferences, and strategic planning for potential future global clinical trials and market entry.
430 E 29th St, Floor 9
New York
New York
United States
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Innovimmune Biotherapeutics' leadership includes:
Innovimmune Biotherapeutics has been backed by several prominent investors over the years, including:
Publicly available information does not indicate significant C-level executive hires or exits at Innovimmune Biotherapeutics, Inc. in the last 12 months. The company maintains a lean executive team focused on its preclinical programs.
Discover the tools Innovimmune Biotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Innovimmune Biotherapeutics, Inc. likely utilizes common corporate email formats. Based on industry standards for a company of its size and type, email addresses are probably structured using combinations of employee names and the company domain 'innovimmune.com'.
[first_initial][last]@innovimmune.com
Format
kbaluch@innovimmune.com
Example
75%
Success rate
GlobeNewswire • April 05, 2023
Innovimmune Biotherapeutics, Inc. announced today that it will present new preclinical data from its first-in-class, orally-administered, small molecule CIT-bezigdomide (INV-108) program for cancer immunotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida, from April 14-19, 2023....more
GlobeNewswire • October 26, 2022
Innovimmune Biotherapeutics, Inc., a preclinical stage biopharmaceutical company, announced today that it will present new preclinical data from its first-in-class, orally-administered, small molecule, innate immune checkpoint inhibitor INV-108 program for cancer immunotherapy at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA and virtually, November 8-12, 2022....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Innovimmune Biotherapeutics, are just a search away.